Search results (1320)
« Back to PublicationsSomatic gene mutation patterns and burden influence outcomes with enasidenib in relapsed/refractory IDH2-mutated AML
Risueño A. et al, (2024), Leukemia Research, 140
Society for Immunotherapy of Cancer (SITC) recommendations on intratumoral immunotherapy clinical trials (IICT): from premalignant to metastatic disease.
Luke JJ. et al, (2024), J Immunother Cancer, 12
A phase I open-label, dose-escalation study of NUC-3373, a targeted thymidylate synthase inhibitor, in patients with advanced cancer (NuTide:301).
Spiliopoulou P. et al, (2024), J Exp Clin Cancer Res, 43
Severe acute myositis and myocarditis on initiation of 6-weekly pembrolizumab post-COVID-19 mRNA vaccination.
Watson RA. et al, (2024), Journal for immunotherapy of cancer, 12
New role of fat-free mass in cancer risk linked with genetic predisposition.
Harris BHL. et al, (2024), Sci Rep, 14
Generating human bone marrow organoids for disease modeling and drug discovery
Olijnik A-A. et al, (2024), Nature Protocols
Nilotinib in KIT-driven advanced melanoma: Results from the phase II single-arm NICAM trial.
Larkin J. et al, (2024), Cell Rep Med, 5
A Phase I Study of the Oral Dual-Acting Pan-PI3K/mTOR Inhibitor Bimiralisib in Patients with Advanced Solid Tumors
Janku F. et al, (2024), Cancers, 16
Changes in bone marrow fibrosis during momelotinib or ruxolitinib therapy do not correlate with efficacy outcomes in patients with myelofibrosis.
Oh ST. et al, (2024), EJHaem, 5, 105 - 116
Efficacy of a Novel BCL-XL Degrader, DT2216, in Preclinical Models of Post-Myeloproliferative Neoplasm Secondary AML
Wang Z. et al, (2024), BLOOD, 144, 2749 - 2751
Implementing human bone marrow organoids to interrogate microenvironmental influences on the efficacy of blood cancer immunotherapies
Wong ZC. et al, (2024), CANCER RESEARCH, 84
Real World Efficacy and Safety of Momelotinib for Myelofibrosis: Evaluation of a UK-Wide Study Confirms 40% Anaemia Response Rate in a Non-Clinical Trial Cohort
Rampotas A. et al, (2024), BLOOD, 144, 1804 - 1806
RUX-AZA Response in AP/BP-MPN Is Driven By Release of the Differentiation Block in Mutant HSPCs: A Single-Cell Multi-Omic Analysis of Responders on the Phase Ib Phazar Study
Brierley CK. et al, (2024), BLOOD, 144, 3146 - 3147
Single-Cell Multiomic Profiling of TP53 Mutated Myelodysplastic Neoplasms- All Clones Are Not Equal
Chowdhury O. et al, (2024), BLOOD, 144, 3615 - 3616
Real-world Effectiveness of Azacitidine in Treatment-Naive Patients With Higher-risk Myelodysplastic Syndromes.
Rajakumaraswamy N. et al, (2023), Clin Lymphoma Myeloma Leuk